JAK1-IN-22
JAK1-IN-22 is a JAK1-selective inhibitor with an IC50 of 1.84 μM. JAK1-IN-22 exerts no significant inhibitory effect on JAK2 and JAK3. JAK1-IN-22 can be used in the research of JAK1-related diseases such as asthma, alopecia areata, and type 1 diabetes.
For research use only. We do not sell to patients.
- CAS No.: 2241039-80-3
- Formula: C28H31F2N7O4S
- Molecular Weight:599.66
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
JAK1 1.84 μM (IC50) |
JAK1-IN-22 (Example 34) inhibits IL-13-induced STAT6 reporter gene activity in U937-STAT6-Luc cells with an IC50 > 4.20 μM; it exhibits an IC50 of 1.84 μM in recombinant JAK1 enzymatic assays, while the IC50 values against JAK2 and JAK3 are both > 30 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2241039-80-3
-
Molecular Weight 599.66
-
Formula C28H31F2N7O4S
-
SMILES
N(C([C@H](COC)N1CCN(C)CC1)=O)C2=C3C(C(=CN3)C4=NC(NC5=C(F)C(S(C)(=O)=O)=CC=C5)=NC=C4F)=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- JAK1-IN-22
- 2241039-80-3
- JAK
- JAK1 inhibitor
- selective JAK1 inhibitor
- Janus kinase 1
- JAK2 sparing
- JAK3 sparing
- indolylpyrimidine
- pyrimidine derivative
- S-enantiomer
- U937 cells
- STAT6 reporter assay
- IL-13 signaling
- asthma
- alopecia areata
- type 1 diabetes
- rheumatoid arthritis
- psoriasis
- lupus
- multiple sclerosis
- atopic dermatitis
- ulcerative colitis
- Crohn's disease
- autoimmune disease
- inflammatory disease
- C3H/HeJ mice
- Brown Norway rats
- OVA lung inflammation model
- Inhibitor
- inhibitor
- inhibit